Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study of Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection in Patients With High Risk of Relapse After Radical Surgery or Ablation of Hepatocellular Carcinoma (HCC).
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 19 May 2023 New trial record